Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company Ltd granted a cannabis research licence

The licence allows Canndeo to build its exclusive Plant Breeders Rights.
The Hydroponics Company Ltd issued a cannabis research licence
Dr Andrew Beehag, CEO of Canndeo, recently presenting to investors

The Hydroponics Company (ASX:THC) is one of the first ASX-listed cannabis companies to have secured a medicinal cannabis research licence.

The license was granted to THC’s wholly owned subsidiary Canndeo Ltd by the Office of Drug Control.

The research licence will allow Canndeo to build its exclusive Plant Breeders Rights (PBR) protected Cannabis sativa strains.

Dr Andrew Beehag, chief executive officer of Canndeo, commented:

"We are very pleased to have been issued a research licence, which effectively paves the way forward for future domestic supply of medicinal cannabis, targeting multiple markets with high purity cannabidiol (CBD) and enabling THC to continue its roll out of high quality imported products as well as locally produced medicines."


Analysis

THC will now advance research into medicinal cannabis to undertake both its own research exploring optimal cultivation and production methodologies and strain development.

The company will also look to the implementation of its epigenetic technology as a key innovation in the field.

The research licence is the first step in establishing Canndeo’s domestic pharmaceutical production capability with anticipated product availability in 2018.

THC has been one of the most successful IPO's of 2017, and shares are expected to open higher today.

The heavily oversubscribed IPO was priced at $0.20 per share, with the company last trading at $0.31 per share.

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

1530537220_Blood-Test.jpg
July 03 2018
The research and diagnostic company develops cancer-detecting blood tests
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
Callitas CEO James Thompson
Sat
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use